Lille

• AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri … Recruiting
  2024-516525-31-01 5 2025-07-14 Primary Biliary Cholangitis
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• SerCaBot-2302 - Serratus Plane Block (SPB) versus Capsaicin versus Botulinum toxin type A for the chronic neuropathic pain of post-mastectom … Recruiting
  2024-517420-20-00 4 2025-06-10 Chronic neuropathic pain of post-mastectomy syndrome
• A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease Recruiting
  2024-515622-80-00 5 2025-06-04 Type 3 Von Willebrand Disease
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• A Study to Investigate ALE.P02 as Monotherapy in Adult Patients with Selected CLDN1+ Solid Tumors Recruiting
  2024-515459-39-00 7 2025-05-08 Advanced or Metastatic Squamous Solid Tumors
• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 5 2025-05-02 melanoma, cutaneous malignant
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn' … Recruiting
  2024-513054-30-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 5 2025-02-24 Haemophilia A
• Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade … Recruiting
  2024-513317-12-00 5 2025-02-05 Pancreatic cancer
• Impact of Inhaled BGF 160 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient Recruiting
  2024-514097-52-00 6 2024-12-16 Impact of inhaled BGF 160 on complexity and variability of tidal breat
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)
• Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial Recruiting
  2024-514799-42-00 4 2024-11-05 IDIOPATHIC PULMONARY FIBROSIS
• A preventive study of bleeding episodes for children with severe von Willebrand disease (VWD). Recruiting
  2023-509877-22-00 5 2024-10-30 severe von Willebrand Disease
• A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno … Recruiting
  2023-510422-32-00 5 2024-09-10 Tenosynovial Giant Cell Tumour
• A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d … Recruiting
  2022-502289-25-00 5 2024-08-28 Moderate to Severe Active Systemic Lupus Erythematosus
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 4 2024-04-08 Mantle Cell Lymphoma (MCL)
• A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers Recruiting
  2023-505165-93-00 1 2024-03-01 Non-Hodgkin Lymphoid Malignancies
• ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc … Recruiting
  2023-505486-92-00 4 2024-02-09 Small bowel adenocarcinoma
• Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Recruiting
  2022-503126-12-01 5 2024-01-05 Hypoparathyroidism

Showing 73–96 of 686 trials